Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference

Strategic Insights -

Active Biotech, a biotechnology company focused on autoimmune/inflammatory diseases and cancer, is scheduled to present at the JP Morgan 31st Annual Healthcare Conference. The presentation will provide an update on the company's development programs, including laquinimod, a novel oral immunomodulatory drug for multiple sclerosis, and ANYARA, a novel concept for tumor therapy in a Phase III study for renal cell cancer. The presentation will also cover the Phase III prostate cancer project TASQ, in co-development with Ipsen, and the pre-clinical ISI project. The audio and slide presentation will be webcasted live on the Active Biotech website.

Key Takeaways:

  • Active Biotech will present its development programs at the JP Morgan 31st Annual Healthcare Conference, including laquinimod, ANYARA, TASQ, and the pre-clinical ISI project.
  • Laquinimod is a novel oral immunomodulatory drug for multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, and is in Phase III development.
  • ANYARA is a novel concept for tumor therapy in a Phase III study for renal cell cancer.
  • TASQ is a Phase III prostate cancer project being developed in co-development with Ipsen.
  • The pre-clinical ISI project is an orally administered compound for Systemic Sclerosis.
  • The presentation will provide an update on the company's pipeline and provide additional insights into its development programs.

Statistics:

  • The JP Morgan 31st Annual Healthcare Conference will take place from January 6-10, 2013, in San Francisco, US.
  • Active Biotech's presentation will be held on January 10, at 8:00 am PST (Pacific Standard Time) / 17:00 Central European Time.
  • Active Biotech has a focus on autoimmune/inflammatory diseases and cancer and has several projects in clinical development, including laquinimod, ANYARA, and TASQ.
  • Laquinimod is in Phase III development for multiple sclerosis, Crohn's, and Lupus.
  • ANYARA is in Phase III development for renal cell cancer.

Sources:

  • Active Biotech website: www.activebiotech.com
  • Thomson Reuters ONE: Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference
  • COMTEX: Lund, Sweden, January 3, 2013 - Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference